Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6384165 | 0.74 | SRD5A2 (0.38) | NPC1RAB9ARECQLSMN1; SMN2POLB | |
| SCHEMBL2124198 | 0.73 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL5045755 | 0.72 | NPC1 (0.60) | NPC1RAB9AKMT2AMAOBRECQL | |
| SCHEMBL15709504 | 0.72 | NPC1 (0.60) | NPC1RAB9AKMT2AMAOBRECQL | |
| SCHEMBL952143 | 0.66 | ELANE (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL38659645 | 0.66 | POLB (0.37) | NPC1KMT2APOLB | |
| SCHEMBL10940882 | 0.66 | NPSR1 (0.54) | CYP2C19NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL27546454 | 0.66 | ELANE (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL4884851 | 0.66 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL2661372 | 0.65 | ALDH1A1 (0.43) | NPC1RAB9AKMT2ARECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577305-A1 | Oral antidiabetic agents | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20030171377-A1 | Antidiabetic agents | BIGGE CHRISTOPHER FRANKLIN (US) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171377-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GLP1R | CYP1A2 971/4885CYP3A4 309/4885CYP2C9 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.